Business
GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®
GoodRx Employer Direct enables self-insured employers to subsidize the $449 Lilly Employer Connect medication price for Zepbound KwikPen to reduce employee
About this update from Goodrx Holdings, Inc.
[{"type":"text","content":"\nGoodRx Employer Direct enables self-insured employers to subsidize the $449 Lilly Employer Connect medication price for Zepbound KwikPen to reduce employee out-of-pocket costs\n\n\nBrief Summary:\n\n\n\nGoodRx to collaborate with Eli Lilly to expand employer-sponsored access to Zepbound® KwikPen®, an FDA-approved dual GIP and GLP-1 obesity treatment\n\n\n\nThrough GoodRx Employer Direct, self-insured employers can subsidize Lilly’s $449 discounted medication price for Zepbound KwikPen\n\n\n\nEmployer contributions are applied to the medication cost, reducing employee out-of-pocket costs\n\n\n\nGoodRx integrates manufacturer discounted pricing and employer funding in real time; optional telemedicine supports prescribing and fulfillment\n\n\n\n SANTA MONICA, Calif.--(BUSINESS WIRE)--\nGoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct. As one of Lilly’s Employer Connect independent program administrators, GoodRx enables self-insured employers to access Zepbound KwikPen at a set price of $449 across all doses, with the flexibility to further subsidize the cost for employees at the pharmacy counter.\n\n\n“Employers are navigating rising demand for GLP-1 obesity treatments and need predictable, transparent affordability solutions,” said Laura Jensen, Chief Commercial Officer & President of Pharma Direct at GoodRx. “Our collaboration with Lilly demonstrates how GoodRx connects manufacturer pricing and employer contributions in a single infrastructure. The result is a scalable model that expands access to Zepbound while supporting long-term sustainability for employers.”\n\n\nA Simplified Model for Employer-Sponsored Access\n\n\nGoodRx Employer Direct enables employers to support access to Zepbound KwikPen without altering their core health benefit structure. Employer contributions to Lilly’s Employer Connect $449 price are applied seamlessly to the medication price, creating a predictable and more transparent pathway for high-demand obesity management medicines. The program is designed to complement, not replace, traditional health plans, offering a simplified access pathway outside traditional formulary controls. Plan sponsors retain flexibility and control over contrib...